Is Eli Lilly Going To $1,100?

"Lilly's Q1 2026 earnings report on April 30 was the catalyst the bulls needed. Revenue came in at $19.799 billion, beating consensus by 11.25% and growing 55.55% YoY. Non-GAAP EPS of $8.55 handily beat the $6.79 consensus estimate. Mounjaro alone delivered $8.662 billion (up 125%), and Zepbound added $4.16 billion."

"Management raised full-year 2026 revenue guidance to $82 billion to $85 billion and Non-GAAP EPS to $35.5 to $37. Even after the rally, LLY is still down 5.33% YTD and sits 7% below its 52-week high of $1,132.06, leaving room to run."

"The bull case rests on Foundayo (orforglipron), Lilly's newly approved oral GLP-1 pill that requires no food or water restrictions. In a head-to-head trial published in The Lancet, orforglipron beat oral semaglutide on blood sugar and weight loss. Retatrutide, Lilly's triple agonist, hit its Phase 3 endpoints in T2D."

"The 24/7 Wall St. price target for Eli Lilly is $1,164.85, implying 14.68% upside from the current price of $1,015.75. We rate Lilly a buy with a 90% confidence level, reflecting strong analyst consensus, accelerating earnings, and defensive sector positioning."

Eli Lilly shares rebounded after a strong Q1 2026 earnings report. Revenue reached $19.799 billion, growing 55.55% year over year and beating consensus by 11.25%. Non-GAAP EPS was $8.55, above the $6.79 consensus estimate. Mounjaro generated $8.662 billion, up 125%, while Zepbound contributed $4.16 billion. Full-year 2026 guidance increased to $82 billion to $85 billion in revenue and $35.5 to $37 in Non-GAAP EPS. A newly approved oral GLP-1 pill, orforglipron, showed favorable results versus oral semaglutide. Additional growth drivers include China NRDL inclusion and progress for retatrutide in Phase 3. Risks include falling realized prices.

Read at 24/7 Wall St.